Strategic Diagnostics' Antibody Revenue Gains Tempered by Ag/GMO Decline

Nov 02, 2007

NEW YORK (GenomeWeb News) — Strategic Diagnostics today said third-quarter revenues were flat as R&D spending rose 9 percent and profit fell around 70 percent.

Total receipts for the three months ended Sept. 30 dipped slightly to $6.56 million from $6.62 million year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Last of the Northern White Rhinoceroses, Sequenced

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

DNA Phenotyping Allowed in Bavaria

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Thanks for the Stress, Dad

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

This Week in Science

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Main menu